TriSalus Life Sciences, Inc.
For the period ended Sep 22, 2026. Filed Sep 22, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Sep 22, 2026 · Filed Sep 22, 2026
Use the contents to explore the available documents and sections.
Contents
Not Applicable
(Former name or former address, if changed since last report)
| Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below): | |
|---|---|
| o | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common stock, $0.0001 par value | TLSI | Nasdaq Global Market |
| Warrants, each whole warrant exercisable for one share of registrant's common stock at an exercise price of $11.50 per share | TLSIW | Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
| Item 8.01 | Other Events. |
|---|
On September 22, 2026, TriSalus Life Sciences, Inc. (the “Company”) issued a press release announcing that it has received U.S. Food and Drug Administration (“FDA”) 510(k) clearance for its TriNav Advance device. With FDA clearance, the Company expects to commence commercialization. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) Exhibits: | |
|---|---|
| Exhibit Number | Description |
| 99.1 | Press Release dated September 22, 2026 |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.